Early Phase 1 signals from Senti Biosciences’ off-the-shelf CAR-NK program in relapsed/refractory AML include MRD-negative, durable complete remissions with a favorable safety profile in a heavily pretreated population. With enrollment now complete, the company is moving to FDA discussions in the first half of 2026 and positioning the program for a pivotal path under its RMAT designation.
The core development is operational: Senti has finished enrolling the first-in-human study of SENTI-202, an allogeneic, logic-gated CAR-NK engineered to target CD33 and/or FLT3 while sparing healthy hematopoietic stem and progenitor cells via an inhibitory “NOT” gate. The company is mapping a registration strategy in R/R AML and evaluating expansion into newly diagnosed and pediatric settings. The RMAT status signals openness to surrogate endpoints and more intensive regulatory guidance, but the company has not yet disclosed denominator-level efficacy or duration data beyond the qualitative claims presented at ASH.
Strategically, this is a bet that cell therapy in AML will require both antigen breadth and hematologic selectivity. AML has resisted CAR approaches largely due to antigen heterogeneity and on-target myeloablation. The OR-gate design addresses antigen escape by recognizing either CD33 or FLT3; the NOT-gate aims to protect normal marrow, a recurring safety limiter for CD33-directed therapies. Calibrated-release IL-15 is intended to boost NK persistence without the cytokine-related toxicities that have dogged some platforms. For regulators, the key question will be whether the NOT-gate translates into timely hematologic recovery and transfusion independence without sacrificing depth of response—data elements that will carry as much weight as headline CR rates.
For sites and CROs, the program’s “off-the-shelf” profile reduces the apheresis and manufacturing queue that constrain autologous approaches, potentially broadening the site footprint and shortening vein-to-treatment timelines. Operational complexity shifts upstream to screening and response assessment: sponsors will need reliable, turnaround-rapid confirmation of CD33/FLT3 expression and standardized MRD assays acceptable to FDA as a response-quality measure. If a pivotal uses a single-arm design typical of RMAT programs, endpoints will likely center on CR/CRi plus MRD clearance and duration; transplant bridging will require careful censoring rules and sensitivity analyses to satisfy regulators on durability. Pediatric exploration introduces additional site selection and safety monitoring demands that will concentrate activity at high-volume academic centers with cell therapy infrastructure.
The competitive and policy context is tightening. With no approved CAR-based therapies in AML, regulators have set a high bar for demonstrating both marrow recovery and sustained disease control. Meanwhile, standards of care in salvage settings continue to evolve around venetoclax-based regimens, menin inhibitors, targeted FLT3 combinations, and CD33-directed agents—raising the evidentiary threshold for any single-arm filing. Manufacturing comparability will matter: donor-derived NK cells, logic gating, and IL-15 expression introduce batch and potency variables that must be locked down ahead of a pivotal.
What to watch next are the hard numbers: response denominators, MRD methodology, median duration, and a granular safety readout—including cytopenia kinetics, infection rates, and neurotoxicity. Regulatory feedback in the first half of 2026 will reveal whether FDA will entertain an accelerated approval on a surrogate package or require a randomized comparator. On the execution side, expect a tight site roster with centralized testing, rigorous endpoint adjudication, and early clarity on transplant handling—determinants that will shape both trial timelines and the credibility of any expedited path.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
